ip-strategy

name

ip-strategy

description

Intellectual property structuring, migration, valuation, and licensing for tax-efficient IP management. USE THIS SKILL when the user asks about IP holding structures, IP licensing, IP migration, IP valuation for tax purposes, technology transfer, cost sharing arrangements, cost contribution arrangements, DEMPE analysis, royalty rate benchmarking, IP box eligibility, IP in M&A, IP carve-outs, defensive IP strategy, freedom to operate, or substance requirements for IP holding entities. Covers patents, trademarks, trade secrets, copyrights, know-how, and data assets.

IP Strategy

Required Inputs

• IP Portfolio Inventory: List of IP assets (patents, trademarks, trade secrets, copyrights, know-how, software, data assets) with registration details and current ownership.
• Group Structure: Entities, jurisdictions, and ownership chain.
• DEMPE Functions: Where IP Development, Enhancement, Maintenance, Protection, and Exploitation activities are currently performed.
• IP-Related Financial Data: Revenue attributable to IP, current royalty flows, R&D expenditure, IP-related costs by entity.
• Strategic Objectives: Tax optimization, IP centralization, M&A preparation, risk mitigation, or licensing monetization.
• Jurisdictions of Interest: Current and planned IP holding locations.
• Existing Agreements: Current license agreements, cost sharing arrangements, and R&D service agreements.
• Regulatory Context: Industry-specific IP regulations, data localization requirements, and export control considerations.

Execution Steps

1. IP Asset Identification and Classification

Conduct a comprehensive IP inventory:

IP Asset	Type	Description	Owner (Legal)	Owner (Economic)	Registration / Status	Jurisdiction	Revenue Attributable ($M)	Remaining Useful Life
[Asset 1]	Patent	[Description]	[Entity]	[Entity]	[Granted / Pending / Trade secret]	[Country]	$___M	___ years
[Asset 2]	Trademark	[Description]	[Entity]	[Entity]	[Registered / Common law]	[Country]	$___M	Indefinite
[Asset 3]	Trade secret	[Description]	[Entity]	[Entity]	[Internal classification]	[Country]	$___M	N/A
[Asset 4]	Copyright	[Description]	[Entity]	[Entity]	[Auto / Registered]	[Country]	$___M	___ years
[Asset 5]	Know-how	[Description]	[Entity]	[Entity]	[Documented / Undocumented]	[Country]	$___M	___ years
[Asset 6]	Data asset	[Description]	[Entity]	[Entity]	[Proprietary / Licensed]	[Country]	$___M	___ years

IP classification matrix:

Classification	Tax Relevance	Valuation Approach	Licensing Model
Patents	Qualify for IP box in most regimes; amortizable; can be contributed tax-free under certain conditions	Relief from royalty, excess earnings	Royalty as % of net sales (typical: 2-8%)
Trademarks	IP box eligibility varies (excluded in many post-BEPS regimes); indefinite life	Relief from royalty, market approach	Royalty as % of net sales (typical: 1-5%)
Trade secrets	May qualify as know-how for IP box; no registration = harder to transfer cleanly	Cost approach, excess earnings	Lump-sum or running royalty
Copyrights / software	Software copyrights qualify for IP box in many jurisdictions; finite life	Relief from royalty, cost approach	Per-unit, per-user, or % of revenue
Know-how	Qualifies if documented and transferable; DEMPE analysis critical	Cost approach, comparable transactions	Technical assistance fee or bundled royalty
Data assets	Emerging area; limited IP box coverage; privacy regulations create complexity	Cost approach, income approach	License fee, data-as-a-service pricing

2. IP Ownership Structure Design

Evaluate alternative ownership structures:

Structure	Description	Tax Advantages	Tax Risks	Best Suited For
Centralized IP HoldCo	Single entity owns all material IP; licenses to operating entities worldwide	IP box eligibility; consolidated royalty income; single licensing point	Substance challenge (DEMPE must be performed); withholding on royalties; CFC risk at parent level	Groups with globally exploited IP; post-M&A IP consolidation
Regional IP HoldCos	IP ownership split by region (e.g., EMEA, APAC, Americas)	Regional treaty access; reduced withholding; distributed risk	Complexity; fragmented ownership; potential for inconsistent policies	Large multinationals with distinct regional markets
Distributed / local ownership	Each operating entity owns IP it develops and uses locally	Simplest; no intercompany royalties; substance automatic	No centralized IP box benefit; no royalty deductions in high-tax jurisdictions	Early-stage companies; single-jurisdiction businesses
Principal company model	One entity is the entrepreneur/principal; owns IP and bears risk; other entities are limited-risk	Aligns with FAR analysis; residual profit in IP owner; routine returns to others	Principal must have genuine substance and decision-making authority	Groups with clear entrepreneurial entity
Cost sharing arrangement	Multiple participants jointly fund IP development and share ownership proportional to anticipated benefit	Each participant owns right to exploit in its territory; no ongoing royalty	Buy-in payment on existing IP; complex to maintain; IRS scrutiny (Section 482)	Joint development between US parent and foreign subsidiary

Recommended structure evaluation:

Factor	Option A: Centralized HoldCo in [Country]	Option B: Principal Model in [Country]	Option C: Cost Sharing
IP box rate available	___%	___%	N/A
Withholding on royalties (weighted avg)	___%	___%	N/A (no royalties)
DEMPE substance achievable?	[Assessment]	[Assessment]	Automatic (development = ownership)
CFC inclusion risk	[Assessment]	[Assessment]	[Assessment]
Implementation complexity	[Low/Med/High]	[Low/Med/High]	[Low/Med/High]
Ongoing compliance cost	$___K/year	$___K/year	$___K/year
Estimated annual tax savings	$___M	$___M	$___M

3. IP Valuation Methodologies

Cross-reference to the valuation skill for full methodology. Key approaches for IP:

3a. Relief from Royalty Method

IP Value = Sum of [Projected Revenue_t x Royalty Rate x (1 - Tax Rate) / (1 + r)^t] for t = 1 to N
         + Terminal Value

Where:
  Royalty Rate = arm's length royalty rate from comparable license agreements
  Tax Rate = tax rate of the hypothetical licensee
  r = discount rate (risk-adjusted; typically WACC + IP-specific premium)
  N = remaining useful life of the IP

Parameter	Value	Basis
Projected revenue (Year 1)	$___M	Management forecast
Revenue growth rate	___%	Historical + market analysis
Arm's length royalty rate	___%	Comparable license analysis
Tax rate	___%	Licensee jurisdiction
Discount rate	___%	WACC + ___ bps IP premium
Remaining useful life	___ years	Patent term / economic life
IP Value (Relief from Royalty)	$___M

3b. Multi-Period Excess Earnings Method (MPEEM)

Used for primary intangible assets — isolates earnings attributable to the IP after deducting returns on all other assets:

Excess Earnings_t = Total Earnings_t
  - Contributory Asset Charge (working capital x required return)
  - Contributory Asset Charge (fixed assets x required return)
  - Contributory Asset Charge (workforce x required return)
  - Contributory Asset Charge (other intangibles x required return)

IP Value = Sum of [Excess Earnings_t / (1 + r)^t] for t = 1 to N + Terminal Value

3c. Cost Approach

Used as a floor value or for early-stage IP where income data is limited:

IP Value = Sum of historical R&D costs to develop the IP
         x (1 + Entrepreneurial profit margin)
         x Obsolescence adjustment (functional, economic, technological)

Cost Element	Amount ($M)	Period
Internal R&D labor	$___M	[Years]
External R&D (contractors)	$___M	[Years]
Materials and supplies	$___M	[Years]
Allocated overhead	$___M	[Years]
Opportunity cost / developer's profit	$___M	___% markup
Less: Obsolescence adjustment	($___M)	___% reduction
IP Value (Cost Approach)	$___M

Valuation reconciliation:

Method	IP Value ($M)	Weight	Weighted Value ($M)
Relief from royalty	$___M	___%	$___M
Excess earnings (MPEEM)	$___M	___%	$___M
Cost approach	$___M	___%	$___M
Concluded IP Value			$___M

4. Licensing Structure Design

4a. License Framework

Element	Inbound License (to IP HoldCo from developer)	Outbound License (from IP HoldCo to OpCo)
License type	Exclusive, worldwide, all fields of use	Non-exclusive, territory-specific, field-specific
Royalty basis	Lump-sum buy-in + ongoing royalty	Running royalty (% of net sales)
Royalty rate	Market rate benchmarked to comparable transactions	Market rate benchmarked to comparable transactions
Sub-licensing rights	Yes — enables outbound licensing	Limited — only within operating territory
Term	Perpetual or IP lifetime	5-10 years, auto-renewing
Minimum royalty	[If applicable]	[If applicable to ensure substance of arrangement]
Payment timing	Quarterly in arrears	Quarterly in arrears

4b. Royalty Rate Benchmarking

Comparability Factor	Comparable 1	Comparable 2	Comparable 3	Subject Transaction
Industry	[Industry]			[Industry]
IP type	[Patent/TM/SW]
Exclusivity	[Exclusive/Non-exclusive]
Territory	[Scope]
Development stage	[Early/Mature]
Revenue base	[Net sales / Gross sales]
Royalty rate	___%	___%	___%
Arm's length range				___% - ___%
Selected rate				___%

Data sources for royalty comparables: RoyaltyStat, ktMINE, SEC filings (license agreements in 10-K/10-Q), BVR/Valuation Advisors, industry surveys.

4c. Withholding Tax on Royalties

Royalty Flow	From (Licensee)	To (Licensor)	Domestic WHT Rate	Treaty Rate	Treaty Cited	Beneficial Owner Test Met?
[Flow 1]	[Entity/Country]	[Entity/Country]	___%	___%	[Treaty article]	Yes/No
[Flow 2]

Net royalty income after WHT and IP box:

Net income = Gross royalty
  - Withholding tax (net of foreign tax credits)
  x IP box effective rate (if applicable)
  = After-tax royalty income

5. IP Migration Planning

5a. Migration Step Plan

Step	Action	Tax Implication	Timeline
1	IP valuation — Determine arm's length value of IP to be transferred	Valuation sets the transfer price; affects gain/loss at transferor	Weeks 1-6
2	Exit tax analysis — Quantify tax on deemed disposition at transferor jurisdiction	Transferor recognizes gain = FMV minus tax basis; exit tax may apply	Weeks 1-4 (concurrent)
3	Transfer pricing documentation — Prepare documentation supporting arm's length consideration	Required to defend transfer price; contemporaneous documentation essential	Weeks 4-8
4	Intercompany agreement execution — IP assignment or license agreement at arm's length	Legal transfer of rights; consideration may be lump-sum, installment, or ongoing payment	Week 8
5	Regulatory filings — Patent/trademark assignment recordings; tax authority notifications	Some jurisdictions require advance notification of IP transfers (e.g., Australia, India)	Weeks 8-12
6	Substance establishment — Ensure receiving entity has DEMPE capability before or at transfer	Substance must exist before IP income flows; retroactive substance does not cure	Weeks 1-8 (must precede step 4)
7	Post-migration monitoring — Verify intercompany flows align with new structure	Ensure royalties are paid on schedule; TP documentation updated annually	Ongoing

5b. Exit Tax Analysis

Jurisdiction	Exit Tax Rule	Applies to IP Transfers?	Rate	Deferral / Exemption Available?
United States	Section 367(d) — deemed royalty over useful life (not lump-sum)	Yes — outbound IP transfers to foreign corp	Ordinary income rates (up to 37% individual / 21% corporate)	No deferral; 20-year deemed income inclusion
Germany	Exit tax on unrealized gains when assets leave German tax jurisdiction	Yes	~30% (corporate + trade tax)	EU/EEA deferral (5 annual installments)
France	Exit tax on unrealized gains	Yes	~25%	EU/EEA deferral under conditions
Australia	CGT on deemed disposal; market value substitution rule	Yes	30% (corporate)	No general deferral
India	Tax on IP transfer; requires prior AO approval for some transfers	Yes	As per transfer pricing + capital gains rates	No
Netherlands	Generally no exit tax on IP (participation exemption may apply to IP gains)	Limited	N/A	Participation exemption may shelter gain
UK	Degrouping charge if transferred within 6 years of intra-group transfer	Conditional	25% (corporate)	Substantial shareholding exemption may apply

Exit tax cost estimate:

IP Asset	FMV ($M)	Tax Basis ($M)	Gain ($M)	Exit Tax Rate	Exit Tax ($M)	Mitigation
[Asset 1]	$___M	$___M	$___M	___%	$___M	[Strategy]
[Asset 2]	$___M	$___M	$___M	___%	$___M	[Strategy]
Total exit tax					$___M

Break-even analysis: Years to recoup exit tax through lower ongoing IP income taxation:

Break-even period = Exit tax cost / Annual tax saving from new structure

6. Cost Sharing / Cost Contribution Arrangement (CCA) Design

Element	Design Decision	Rationale
Participants	[List entities and territories]	Each must reasonably anticipate benefit from IP
Scope of IP	[Specific IP being jointly developed]	Clearly defined to avoid scope creep disputes
Cost pool	[R&D costs, direct and indirect]	All costs related to developing the covered IP
Allocation key	[Reasonably anticipated benefits — typically projected revenue or operating profit by territory]	Must reflect anticipated benefit, not actual results
Buy-in payment	[Lump-sum or installment for pre-existing IP contributed]	Arm's length value of existing IP made available to the arrangement
Buy-out provisions	[Payment if participant exits arrangement]	Must reflect FMV of interest relinquished
PCT payments (US)	[Platform Contribution Transaction — arm's length consideration for existing IP]	Required under Section 482 cost sharing regulations
Annual true-up	[Mechanism to adjust if actual costs differ from projections]	Ensures ongoing arm's length allocation

CCA vs. licensing comparison:

Factor	Cost Sharing / CCA	Licensing Model
Upfront cost	High (buy-in for pre-existing IP)	Low (no buy-in)
Ongoing payments	Share of R&D costs (proportional to anticipated benefit)	Royalty (% of revenue or profits)
IP ownership	Each participant owns rights in its territory	Licensor retains ownership; licensee has use rights only
DEMPE alignment	Each participant must perform DEMPE for its territory	Licensor performs DEMPE; licensee performs exploitation only
Flexibility to exit	Buy-out payment required	License termination per agreement terms
IRS/tax authority scrutiny	High (Section 482 regulations; Altera case history)	Moderate (standard arm's length analysis)
Best for	Genuinely joint development with shared expertise	IP owner controls development; licensees exploit locally

7. DEMPE Functions Substance Requirements

The OECD Guidelines (Chapter VI) require that the entity claiming IP income must perform — or control and bear the financial risk of — the DEMPE functions:

DEMPE Function	Description	Substance Indicators	Minimum Requirements
Development	Creating and improving the IP	R&D personnel; lab/development facilities; decision authority over R&D direction	Qualified employees directing R&D strategy; budget authority
Enhancement	Upgrading and extending the IP	Engineers/scientists improving existing IP; versioning; feature additions	Personnel working on IP improvements; documented enhancement roadmap
Maintenance	Preserving the value and utility of the IP	Quality assurance; bug fixes; renewals; patent maintenance fees	Staff maintaining IP; budget for maintenance activities
Protection	Legal and practical protection of IP rights	IP counsel; patent prosecution; litigation management; trade secret programs	Legal team or supervised external counsel; IP protection policies
Exploitation	Commercializing and monetizing the IP	Licensing negotiations; marketing strategy; pricing decisions; distribution	Commercial decision-makers; licensing/sales team

Substance assessment per entity:

Entity	D	E	M	P	E	Overall Substance Rating	Gap
[IP HoldCo]	[Strong/Adequate/Weak]					[Sufficient / Insufficient]	[Description]
[R&D Entity]	[Strong/Adequate/Weak]
[OpCo 1]	[Strong/Adequate/Weak]

Minimum substance benchmarks for IP holding entities:

Requirement	Benchmark	Current Status	Action Needed
Qualified employees	3-5 minimum with IP management expertise	[Current count]	[Hire / Relocate]
Board / management	Local directors with authority over IP decisions	[Current composition]	[Appoint / Empower]
Office and facilities	Genuine office (not just registered address)	[Current setup]	[Lease / Expand]
Operating expenditure	Proportional to IP income (no empty shell)	$___M current	[Increase / Justify]
Decision-making records	Board minutes documenting IP strategy decisions	[Available / Not available]	[Implement governance protocol]
Contracts with service providers	Outsourced DEMPE functions under HoldCo's control and direction	[In place / Missing]	[Draft service agreements]

8. IP Box Regime Eligibility and Benefit Analysis

Assess eligibility for IP box in the IP holding jurisdiction:

Requirement	Threshold	Entity Status	Eligible?
Qualifying IP type	[Per regime — patents, software, etc.]	[IP types held]	Yes/No
Nexus fraction	Must be >0%; benefit scales with fraction	___% (see calculation below)	Yes — ___% of income qualifies
Income tracking	IP income must be tracked per qualifying asset	[System in place / Not in place]	Yes/No
Election / registration	[Per regime requirements]	[Filed / Not filed]	Yes/No
Minimum holding period	[If applicable]	[Holding period met?]	Yes/No

Nexus fraction calculation:

Nexus Fraction = (QE + UPE) / OE

Where:
  QE = Qualifying Expenditure (in-house R&D + outsourced R&D to unrelated parties)
  UPE = Uplift (30% of QE, capped so QE + UPE does not exceed OE)
  OE = Overall Expenditure (QE + acquisition cost of IP + outsourced R&D to related parties)

Component	Amount ($M)	Notes
In-house R&D expenditure	$___M	Employees performing qualifying R&D
Outsourced R&D (unrelated parties)	$___M	Third-party R&D contractors
Qualifying Expenditure (QE)	$___M	Sum of above
30% Uplift (UPE)	$___M	Min(30% x QE, OE - QE)
Numerator (QE + UPE)	$___M
IP acquisition cost	$___M	Purchase price of acquired IP
Outsourced R&D (related parties)	$___M	Intercompany R&D charges
Overall Expenditure (OE)	$___M	QE + acquisition + related-party outsourcing
Nexus Fraction	___%	(QE + UPE) / OE

Benefit calculation:

IP box benefit = Qualifying IP income x Nexus fraction x (Standard rate - IP box rate)
Annual benefit = $___M x ___% x (___% - ___%) = $___M

9. Defensive IP Strategy

Component	Analysis	Recommendation
Freedom to operate (FTO)	[Assessment of third-party IP that could block commercial activities]	[Obtain licenses / Design around / Challenge validity]
IP audit	[Review of all IP assets for proper documentation, registration, and protection]	[Register unregistered IP; document trade secrets; update assignments]
Employee IP agreements	[Status of IP assignment clauses in employment contracts]	[Standardize across jurisdictions; include post-employment restrictions]
Contractor IP agreements	[Status of IP ownership clauses in contractor agreements]	[Ensure work-for-hire or assignment; address pre-existing IP]
IP insurance	[Coverage for infringement claims, both defensive and offensive]	[Evaluate IP insurance policies; cost-benefit analysis]
Trade secret program	[Status of trade secret identification, classification, and protection measures]	[Implement classification system; access controls; NDA program]
Enforcement strategy	[Approach to monitoring and enforcing IP rights against infringers]	[Watch services; graduated enforcement (cease-and-desist, negotiation, litigation)]
Open source compliance	[Review of open source software usage and license compliance]	[Audit; implement approval workflow; ensure license compatibility]

10. IP in M&A Context

Scenario	Tax Considerations	Recommended Approach
IP acquisition (asset deal)	Buyer allocates purchase price to IP (Section 1060 allocation); amortizes over 15 years (Section 197) or useful life	Maximize allocation to short-lived / depreciable IP; step-up benefit calculation
IP carve-out (pre-sale)	Transfer IP out of target before sale; may trigger gain at target; affects target valuation	Evaluate exit tax vs. sale price impact; timing relative to deal signing
IP contribution to JV	Section 351 (US) or local equivalent for tax-free contribution; must control resulting entity	Verify control threshold; document FMV at contribution
IP licensing post-deal	New intercompany IP license between acquirer group and target; arm's length royalty required	Benchmark royalty rate; integrate into deal economics
IP in spin-off	Section 355 requirements; IP must be part of active trade or business	Verify IP is integral to spun-off business; avoid device
IP representations & warranties	Target reps on IP ownership, freedom from encumbrance, non-infringement	Tax indemnity for IP-related tax exposures (transfer pricing, IP box claims)

IP step-up benefit calculation (asset deal):

IP Asset	Allocated Value ($M)	Tax Basis Before ($M)	Step-Up ($M)	Amortization Period	Annual Deduction ($M)	Tax Rate	Annual Tax Benefit ($M)	NPV of Step-Up ($M)
[Asset 1]	$___M	$___M	$___M	___ years	$___M	___%	$___M	$___M
[Asset 2]	$___M	$___M	$___M	___ years	$___M	___%	$___M	$___M
Total								$___M

11. Anti-Avoidance Considerations

Risk	OECD Reference	Description	Mitigation
Nexus approach (BEPS Action 5)	Action 5 Final Report	IP box benefits limited by nexus fraction; substance required	Maximize in-house R&D; minimize related-party outsourcing
DEMPE substance (BEPS Actions 8-10)	Ch. VI, OECD Guidelines	IP income must be commensurate with DEMPE functions performed	Ensure IP HoldCo has real people, real decisions, real risk-bearing
Hard-to-value intangibles (HTVI)	Ch. VI, Section D.4	Tax authorities may use ex-post outcomes to challenge ex-ante valuations	Conservative valuation; price adjustment clauses; contemporaneous documentation
Recharacterization	Ch. I, Section D.2	Tax authority may recharacterize a transaction if it lacks commercial rationality	Ensure arrangement is commercially rational for all parties
Principal Purpose Test (PPT)	MLI Article 7	Treaty benefits denied if principal purpose is to obtain treaty benefit	Document non-tax commercial reasons for structure
CFC inclusion of IP income	Various (Subpart F, GILTI, CFC rules per jurisdiction)	Passive royalty income may be included in parent's income currently	Active business exception; high-tax exclusion; check-the-box planning
Transfer pricing on IP transfers	Ch. IX, OECD Guidelines	IP migration must be at arm's length value; commensurate with income standard (US)	Robust valuation; consider price adjustment mechanism
Economic substance legislation	Cayman, BVI, Channel Islands, UAE, etc.	Entities must demonstrate adequate substance for IP holding activities	Meet minimum substance requirements per jurisdiction

Overall anti-avoidance risk rating:

Structure Element	Risk Level	Confidence in Defense	Priority Mitigation
IP ownership location	[Low/Med/High]	[Strong/Adequate/Weak]	[Action]
DEMPE substance	[Low/Med/High]	[Strong/Adequate/Weak]	[Action]
Royalty pricing	[Low/Med/High]	[Strong/Adequate/Weak]	[Action]
IP migration valuation	[Low/Med/High]	[Strong/Adequate/Weak]	[Action]
Treaty access / WHT reduction	[Low/Med/High]	[Strong/Adequate/Weak]	[Action]
CFC exposure	[Low/Med/High]	[Strong/Adequate/Weak]	[Action]

12. Implementation Roadmap

Phase	Timeline	Actions	Deliverables	Dependencies
1. Assessment	Weeks 1-4	IP inventory; DEMPE mapping; current structure analysis; identify target structure	IP register; DEMPE matrix; options memo	Access to IP records, R&D team interviews
2. Valuation	Weeks 3-8	Value IP assets using appropriate methodology; benchmark royalty rates	Valuation report; royalty benchmarking study	Financial data; comparable license data
3. Structure Design	Weeks 5-10	Select IP holding location; design license/CCA structure; draft intercompany agreements	Structure memo; draft agreements	Tax opinion on structure; legal review
4. Substance Building	Weeks 6-16	Hire/transfer qualified employees to IP HoldCo; establish office; implement governance	Employment contracts; office lease; board resolution	Recruitment; immigration (if cross-border)
5. IP Migration	Weeks 12-20	Execute IP assignments; file regulatory recordings; implement transfer pricing documentation	Executed assignments; patent/TM recordings; TP local file	Valuation complete; substance in place
6. Operational Launch	Weeks 16-24	Activate licensing flows; implement royalty payment processes; update accounting systems	First royalty invoices; updated intercompany accounts	IT/finance systems; banking setup
7. Regulatory Filings	Weeks 20-28	IP box election; tax return filings; CbCR updates; any advance ruling applications	Filed elections; updated CbCR; ruling application	Local tax advisor; filing deadlines
8. Monitoring	Ongoing	Annual DEMPE review; TP documentation update; nexus fraction recalculation; substance audit	Annual compliance package	Internal tax team; external advisors

Regulatory filing checklist:

Filing	Jurisdiction	Deadline	Status
Patent/trademark assignment recording	[IP offices per jurisdiction]	[Varies — typically 3-6 months]	[ ]
IP box election	[IP HoldCo jurisdiction]	[With tax return]	[ ]
Transfer pricing documentation	[Each jurisdiction]	[With tax return or on request]	[ ]
CbCR update	[Parent jurisdiction]	[12 months after fiscal year end]	[ ]
Advance ruling application (if desired)	[IP HoldCo jurisdiction]	[Before implementation]	[ ]
Foreign investment notification	[If applicable]	[Varies]	[ ]
Export control license (if applicable)	[Transferor jurisdiction]	[Before IP transfer]	[ ]

Output Template

## IP Strategy: [Client / Group Name]

**Date**: [Date] | **Prepared by**: Tax Advisory Practice
**Objective**: [IP structuring objective]

> This analysis provides a strategic framework for tax planning. It does not
> constitute tax advice or a legal opinion. Implementation requires review by
> qualified tax counsel in each relevant jurisdiction. Tax laws change
> frequently; all analysis is based on current rules as of the date provided.

---

### 1. IP Portfolio Summary

| IP Asset | Type | Owner | Revenue ($M) | Useful Life | Value ($M) |
|---|---|---|---|---|---|
| [Asset] | [Type] | [Entity] | $___M | ___ years | $___M |

**Total IP portfolio value**: $___M

### 2. Current DEMPE Analysis

| DEMPE Function | Currently Performed By | Substance Rating |
|---|---|---|
| Development | [Entity/Location] | [Strong/Adequate/Weak] |
| Enhancement | [Entity/Location] | [Strong/Adequate/Weak] |
| Maintenance | [Entity/Location] | [Strong/Adequate/Weak] |
| Protection | [Entity/Location] | [Strong/Adequate/Weak] |
| Exploitation | [Entity/Location] | [Strong/Adequate/Weak] |

### 3. Recommended IP Structure

[Narrative description with entity diagram]

**IP holding entity**: [Entity name, jurisdiction, role]
**Substance plan**: [Employees, office, governance]

### 4. IP Valuation

| Method | IP Value ($M) | Weight |
|---|---|---|
| Relief from royalty | $___M | ___% |
| Excess earnings | $___M | ___% |
| Cost approach | $___M | ___% |
| **Concluded value** | **$___M** | |

### 5. Licensing Design

| License | Licensor | Licensee | Royalty Rate | Annual Flow ($M) | WHT |
|---|---|---|---|---|---|
| [License] | [Entity] | [Entity] | ___% | $___M | ___% |

### 6. IP Migration Plan (if applicable)

| IP Asset | From | To | Value ($M) | Exit Tax ($M) | Break-Even (Years) |
|---|---|---|---|---|---|
| [Asset] | [Entity] | [Entity] | $___M | $___M | ___ |

### 7. IP Box Benefit

**Nexus fraction**: ___%
**Effective rate**: ___% (vs. standard ___%)
**Annual benefit**: $___M | **NPV (10-year)**: $___M

### 8. Anti-Avoidance Risk Assessment

| Risk | Level | Defense Strength | Mitigation |
|---|---|---|---|
| DEMPE substance | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |
| Nexus approach | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |
| CFC inclusion | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |
| HTVI challenge | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |
| Treaty PPT | [Low/Med/High] | [Strong/Adequate/Weak] | [Action] |

### 9. Defensive IP Strategy

[FTO assessment, IP audit findings, trade secret program recommendations]

### 10. Implementation Roadmap

| Phase | Timeline | Key Actions | Owner |
|---|---|---|---|
| Assessment | Weeks 1-4 | [Actions] | [Team] |
| Valuation | Weeks 3-8 | [Actions] | [Team] |
| Structure design | Weeks 5-10 | [Actions] | [Team] |
| Substance building | Weeks 6-16 | [Actions] | [Team] |
| Migration | Weeks 12-20 | [Actions] | [Team] |
| Operational launch | Weeks 16-24 | [Actions] | [Team] |

### Key Recommendations

1. [Priority recommendation with estimated benefit and timeline]
2. [Second priority recommendation]
3. [Third priority recommendation]

### Cross-References
- `valuation` skill for detailed IP valuation methodologies
- `tax-structure-advisory` skill for holding company jurisdiction selection
- `transfer-pricing` skill for royalty rate benchmarking and TP documentation
- `tax-incentive-analysis` skill for IP box eligibility and R&D credit interaction

Quality Checks

• All analysis is clearly labeled as an analytical framework, not legal advice; disclaimer is included.
• Complete IP inventory with classification, ownership, jurisdiction, and revenue attribution for every asset.
• IP ownership structure options evaluated with at least three alternatives compared on tax savings, risk, and complexity.
• IP valuation uses at least two methodologies with reconciliation and concluded value.
• Royalty rate benchmarking uses comparable license agreements with documented comparability factors.
• Withholding tax on royalties is analyzed for each flow with treaty rates and beneficial ownership assessment.
• IP migration plan includes exit tax analysis with break-even calculation.
• Cost sharing / CCA design (if applicable) includes buy-in calculation, allocation key, and annual true-up mechanism.
• DEMPE substance analysis covers all five functions with specific indicators and minimum requirements per entity.
• Substance requirements include minimum headcount, local management, office, and operating expenditure benchmarks.
• IP box eligibility assessed with nexus fraction calculation per BEPS Action 5.
• Anti-avoidance assessment covers nexus approach, DEMPE, HTVI, recharacterization, PPT, CFC, and economic substance.
• Defensive IP strategy includes FTO, IP audit, employee/contractor agreements, and enforcement approach.
• IP in M&A context (if applicable) includes step-up benefit NPV calculation.
• Implementation roadmap includes phases, timeline, deliverables, dependencies, and regulatory filing checklist.
• Cross-references to related skills (valuation, tax-structure-advisory, transfer-pricing, tax-incentive-analysis) are included.